ClinicalTrials.gg
CompletedNCT07930910SABR-BladderUpdated Nov 12, 2026

Dose-Escalation Stereotactic Ablative Radiotherapy for Ultra-Elderly Bladder Cancer

An observational study in Bladder Cancer, sponsored by Peking University First Hospital. Completed at 1 site in China. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Peking University First Hospital · Observational

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
13
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Enrollment
51st of 53
13 · median 266
Started
2021
with 24 others
Observational
53 of 194
28 open now
Registered
166th of 194
by date

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 51st largest by enrollment of the 53 observational ones that give a count, is one of 25 that started in 2021, is one of 53 observational ones, and was the 166th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this ambispective cohort study is to evaluate the safety and palliative efficacy of a dose-escalated stereotactic ablative radiotherapy (SABR) protocol in ultra-elderly patients (age > 75) with medically inoperable bladder cancer. This study combines a retrospective analysis of early clinical cases with a prospective observation of subsequent patients treated under the same institutional protocol.

The main questions it aims to answer are:

  1. What is the safety profile and durability of symptom control (specifically hemostasis) of a 5-fraction SABR regimen for focal bladder tumors in this fragile population?
  2. Does dose escalation (from 30 Gy to 40 Gy) impact the occurrence of dose-limiting toxicities (DLTs)? As an ambispective study utilizing a 3+3 design-based logic, there is no separate comparison group. Researchers evaluate four dose levels (30 Gy, 35 Gy, 37.5 Gy, and 40 Gy) to observe if higher radiation doses improve local control without increasing severe side effects.

Participants in this cohort:

  1. Received/Receive SABR delivered in 5 daily fractions to the primary bladder tumor, with a 'safety-first' optimization strategy that prioritized OAR sparing over target coverage.
  2. Are evaluated for DLTs and followed up for Hematuria-Free Survival (HFS) and overall survival.
03

Conditions studied

  • Bladder Cancer

Keywords

  • Bladder cancer
  • Stereotactic ablative radiotherapy
  • Elderly
  • Palliative radiotherapy
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of ultra-elderly patients (aged >75 years) diagnosed with biopsy-confirmed urothelial carcinoma of the bladder (T2-T4N0M0). These participants were candidates for palliative radiotherapy due to being medically inoperable or unwilling to undergo radical cystectomy. The cohort includes 16 consecutive patients following a standardized institutional dose-escalation protocol. The population is divided into a retrospective cohort (the first 10 patients) and a prospective cohort (the subsequent 6 patients), all of whom met identical clinical inclusion criteria to ensure data consistency.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of primary bladder cancer (urothelial carcinoma).
  • Patients must be > 75 years of age.
  • Medically inoperable or refusal of surgery
  • Presence of a localized primary bladder lesion evaluable by CT, MRI, or PET-CT.

Exclusion criteria

Exclusion Criteria:

  • Widespread disease.
  • Prior pelvic radiotherapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
13 participants (actual)
Patient registry
No

Groups and cohorts

  • Arm 1

    Dose Level 1: 30 Gy in 5 Fractions

    Radiation: Dose Level 1

  • Arm 2

    Dose Level 2: 35 Gy in 5 Fractions

    Radiation: Dose Level 2

  • Arm 3

    Dose Level 3: 37.5 Gy in 5 Fractions

    Radiation: Dose Level 3

  • Arm 4

    Dose Level 4: 40 Gy in 5 Fractions

    Radiation: Dose Level 4

Interventions

  • RadiationDose Level 1

    Dose Level 1: 30 Gy in 5 Fractions

  • RadiationDose Level 2

    Dose Level 2: 35 Gy in 5 Fractions

  • RadiationDose Level 3

    Dose Level 3: 37.5 Gy in 5 Fractions

  • RadiationDose Level 4

    Dose Level 4: 40 Gy in 5 Fractions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of five-fraction SABR

    Description: The MTD is the highest dose level at which no more than one of three, or one of six, participants has a dose-limiting toxicity (DLT). A DLT is any radiotherapy-related adverse event of Grade 3 or higher (NCI CTCAE v5.0) occurring within 7 months after completion of SABR.

    Time frame: Up to 7 months after completion of SABR

Secondary outcomes

  1. Acute radiotherapy-related toxicity

    Number of participants with radiotherapy-related adverse events graded with NCI CTCAE v5.0, from the start of SABR to 3 months after completion of SABR.

    Time frame: Up to 3 months after completion of SABR

  2. Late radiotherapy-related toxicity

    Number of participants with radiotherapy-related adverse events graded with NCI CTCAE v5.0, occurring more than 3 months after completion of SABR

    Time frame: From 3 months to 24 months after completion of SABR

  3. Symptomatic response rate

    The percentage improvement in cancer-related symptoms (hematuria, frequency, dysuria)

    Time frame: At 3-month intervals, assessed up to 24 months

  4. Local recurrence (LR)

    defined as an enlarging lesion within the PTV defined by RECIST 1.1 criteria

    Time frame: At 3-month intervals, assessed up to 24 months

  5. Overall Survival (OS)

    Overall survival is defined as the time from the date of the first fraction of SABR to the date of death from any cause. For patients who remain alive at the time of the last follow-up, survival time will be censored at the date of the last contact.

    Time frame: From the start of SABR treatment until the date of death or last follow-up (assessed up to 2 years).

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, 100034, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Sep 2025, 45 months.

Of 168 non-industry observational studies under Urinary Bladder Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30. This study's 45 months is below that.

Counting every sponsor, half of 203 studies reached it within 58 months; a quarter within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Nov 12, 2026
StartActual
Dec 1, 2021
Primary completionActual
Sep 20, 2025
CompletionActual
Jan 11, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07930910
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Dec 1, 2021
Primary completion
Sep 20, 2025
Completion
Jan 11, 2026
Last update
Nov 12, 2026

Study contacts

Xianshu Gao, PhD
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion